Wedbush Reiterates Outperform on Aprea Therapeutics, Maintains $7 Price Target

Benzinga Newsdesk www.benzinga.com Negative 63.0%

Neg 63% Neu 0% Pos 0%

Wedbush analyst Robert Driscoll reiterates Aprea Therapeutics (NASDAQ:APRE) with a Outperform and maintains $7 price target.